Related Experiment Video
Updated: Jan 7, 2026
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Sorafenib-associated Trichodysplasia Spinulosa versus Follicular Hyperkeratosis: a case report
Reem Hasan1, Nemat Alsaghir1, Kinda Alshawa1
1Department of Dermatology and Venereology, Damascus University, Damascus, Syria.
Abstract:
Sorafenib is a multi-target kinase inhibitor used to treat advanced cancers, such as hepatocellular carcinoma. It has been associated with various cutaneous adverse events and here we report a new potential skin reaction-Trichodysplasia Spinulosa (TS)-and explore its differential diagnosis with Follicular Hyperkeratosis (FH), both possibly induced by Sorafenib. we highlight the role of sorafenib in disrupting skin keratinization process and propose a mechanism for this reaction, especially in immunosuppressed individuals.
Insights
Sorafenib, a cancer drug, may cause a rare skin reaction called Trichodysplasia Spinulosa (TS). This study explores TS and Follicular Hyperkeratosis (FH) as potential Sorafenib-induced skin conditions.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Sorafenib is a multi-target kinase inhibitor for advanced cancers like hepatocellular carcinoma.
- Sorafenib is known to cause various cutaneous adverse events.
- Skin reactions require careful differential diagnosis to ensure appropriate patient management.
